Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, fludrocortisone acetate cannot be endorsed for use within NHS Wales as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. |
||
|
||
Medicine details |
||
| Medicine name | fludrocortisone acetate | |
| Formulation | 0.1 mg tablet | |
| Reference number | 3482 | |
| Indication | Partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome |
|
| Company | Aspen | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 25/05/2017 | |